Register Login
Register to leave comments
  • News bot May 7, 2026, 11:12 a.m.

    📋 BEAM THERAPEUTICS INC. (BEAM) - Financial Results

    Filing Date: 2026-05-07

    Accepted: 2026-05-07 07:06:11

    Event Type: Financial Results

    Event Details:

    BEAM THERAPEUTICS INC. (BEAM) Reports the reporting period Financial Results BEAM THERAPEUTICS INC. (BEAM) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: 31738
    • Net Income: $94
    • EPS: Not disclosed
    • Cash and equivalents: 1211652
      • Anticipated in 2026
      • targeting therapy for alpha-1 antitrypsin deficiency (AATD) that addresses the underlying pathophysiology of both liver and lung disease.•In March, Beam announced updated safety and efficacy data from the ongoing Phase 1/2 trial of BEAM-302. Treatment with BEAM-302 led to rapid and durable increases of total and functional AAT, decreases in mutant Z-AAT, and new production of corrected M-AAT, with a well-tolerated safety profile across single doses up to 75 mg. •Amy Simon, M.D., chief medical officer of Beam, will give a presentation on translating scientific discovery in gene editing to clinical progress for patients with lung disease, featuring the recent clinical data from the BEAM-302 trial, at the upcoming American Thoracic Society (ATS) International Conference 2026

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    In Thousands Cash Equivalents Marketable Securities 1.21M 1.25M $-33.56K -2.69%
    Operating Expenses Loss From Operations 107.22K 119.29K $-12.07K -10.12%
    Other Income Expense Total Other Income Expense 12.90K 10.96K $1.94K +17.72%
    Other Income Expense Net Loss 94.32K 108.33K $-14.01K -12.93%
    Other Income Expense Net Loss Per Share 0.91 1.23 $-0.32 -26.02%
    Cash and Marketable Securities 1.21M 1.25M $-33.56K -2.69%
    Revenue 31.74K 7.47K $24.27K +324.87%
    Loss from Operations 107.22K 119.29K $-12.07K -10.12%
    Net Loss 94.32K 108.33K $-14.01K -12.93%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: BEAM THERAPEUTICS INC.
    • Ticker Symbol: BEAM

Search

News categories